Stock Analiz

Longeveron Inc. LGVN

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$2.49Market cap $8M
Open the interactive analysis →

Longeveron Inc. (LGVN) is a healthcare company listed in the US with a market value of about $8M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$22M, a net margin of -1921.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).

Key numbers: a P/E of 0.3, 5-year revenue growth of -27% a year, a 5-year average ROIC of -125%.

About Longeveron

Longeveron is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $6M in 2020 to $1M in 2025, a decline of about 26.6% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 738% over three years (dilution for shareholders). It spends 1004% of revenue on research and development.

Score: 1.0 / 5

Value2/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)0.3
Forward P/E—
P/FCF—
P/S7.2
P/B1.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-216.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-49.9%
Revenue growth (5 yrs, per year)-26.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1685.6%
ROIC (5-yr avg.)-124.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$1M$1M$2M$709000$1M$1M$6M
Net income-$22M-$23M-$16M-$21M-$19M-$17M-$4M
Free cash flow-$18M-$19M-$15M-$19M-$15M-$10M-$2M
EPS (diluted)$7.12$-1.29$-2.62$-10.22$-0.01$-0.01$-0.00
Net margin-1921.7%-1893.6%-667.8%-3020.2%-1541.3%-1305.1%-66.1%
ROIC—-283.1%-55.9%-189.2%-61.7%-34.0%-50.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $61.25, 2360% above the current price; targets range from $42.50 to $80.00; the consensus rating is “none”; expected EPS is $-7.20 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Longeveron’s P/E ratio?

About 0.3, based on the last twelve months of diluted earnings per share.

Does Longeveron pay a dividend?

Not currently.

Is Longeveron a good stock to buy?

We do not give buy or sell advice. Longeveron scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.